Quercetin
- Generic Name
- Quercetin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H10O7
- CAS Number
- 117-39-5
- Unique Ingredient Identifier
- 9IKM0I5T1E
- Background
Quercetin is a flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin.
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Phase 2
Not yet recruiting
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Positron Emission Tomography
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 44
- Registration Number
- NCT06940297
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Quercetin Effect on Post-ceserean Pain
Phase 3
Completed
- Conditions
- Post Operative PainCesarean Section Complications
- Interventions
- Other: Placebo
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Future University in Egypt
- Target Recruit Count
- 80
- Registration Number
- NCT06650891
- Locations
- 🇪🇬
El Matarya Teaching Hospital,, Cairo, Egypt
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Drug: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT06355037
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Biological Effects of Quercetin in COPD Phase II
Phase 2
Recruiting
- Conditions
- Chronic Obstructive Pulmonary DiseaseEmphysemaChronic Bronchitis With Airway Obstruction
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Temple University
- Target Recruit Count
- 30
- Registration Number
- NCT06003270
- Locations
- 🇺🇸
Nathaniel Marchetti, Philadelphia, Pennsylvania, United States
Effect of Quercetin in Treatment of Periodontitis
Phase 1
Not yet recruiting
- Conditions
- Inflammation Gum
- Interventions
- Device: scaling and root planing
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 20
- Registration Number
- NCT05928546
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Phase 2
Recruiting
- Conditions
- SchizophreniaTreatment Resistant DepressionAging, Premature
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT05838560
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Phase 2
Recruiting
- Conditions
- Healthy LifestyleObesity
- Interventions
- Procedure: Abdominal adipose tissue biopsyOther: Lifestyle InterventionDrug: Placebo
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 160
- Registration Number
- NCT05653258
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
Phase 2
- Conditions
- Oral Cancer
- Interventions
- Drug: Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 1000000
- Registration Number
- NCT05456022
- Locations
- 🇪🇬
11 Saraya El Manial, Cairo, Egypt
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Lewis Lipsitz
- Target Recruit Count
- 15
- Registration Number
- NCT05422885
- Locations
- 🇺🇸
Hebrew Senior Life, Boston, Massachusetts, United States
Quercetin in Coronary Artery By-pass Surgery
Phase 2
Active, not recruiting
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Montreal Heart Institute
- Target Recruit Count
- 100
- Registration Number
- NCT04907253
- Locations
- 🇨🇦
Montreal Heart Institute, Montréal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath